TL;DR: The Centers for Medicare & Medicaid Services modified NCD 205, the National Coverage Determination governing Medicare sweat test coverage, effective March 7, 2026. Here's what billing teams need to know.
The CMS sweat test coverage policy under NCD 205 draws a hard line: Medicare covers the sweat test for cystic fibrosis diagnosis, and nothing else. The policy explicitly excludes sweat testing used as a predictor of sympathectomy efficacy in peripheral vascular disease—calling that application unproven. This is a focused NCD with a narrow covered indication, and if your billing team isn't documenting the right diagnosis, you're looking at claim denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS / Medicare |
| Policy | Sweat Test — NCD 205 |
| Policy Code | NCD 205 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Pulmonology, Pediatrics, Internal Medicine, Peripheral Vascular Surgery |
| Key Action | Confirm all sweat test claims are linked to cystic fibrosis diagnosis—any other indication is non-covered under Medicare |
CMS Sweat Test Coverage Criteria and Medical Necessity Requirements 2026
NCD 205 is the National Coverage Determination that governs whether Medicare covers the sweat test. The Centers for Medicare & Medicaid Services maintains this policy under the Diagnostic Tests benefit category.
The covered indication is specific: the sweat test is covered when used to diagnose cystic fibrosis. That's it. CMS doesn't cover it for any other purpose under this NCD.
Medical necessity here hinges entirely on clinical context. If a patient presents with signs or symptoms consistent with cystic fibrosis and the ordering provider documents that the sweat test is being used to confirm or rule out that diagnosis, you have a covered service. Without that documentation, you don't.
The policy does not mention prior authorization requirements for the sweat test. That said, individual Medicare Administrative Contractors may impose additional local coverage determination requirements in your region. Check with your MAC before assuming national coverage alone is sufficient.
One thing that stands out about this coverage policy: it's unusually lean. NCD 205 does not list specific CPT or HCPCS codes—more on that below. That puts more weight on your diagnosis coding and clinical documentation to carry the claim. Reimbursement depends on correct ICD-10 coding tied to cystic fibrosis, not on a specific procedure code being on an approved list.
CMS Sweat Test Exclusions and Non-Covered Indications
This is where the policy gets pointed. CMS explicitly flags one non-covered use: the sweat test as a predictor of sympathectomy efficacy in peripheral vascular disease.
The policy language calls this application "unproven." That's CMS telling you not to expect reimbursement—and if you bill it, expect a claim denial. This isn't a gray area or a coverage gap waiting to be resolved. CMS has made a definitive determination.
Why does this matter for peripheral vascular practices? Because sympathectomy is still performed in select cases of peripheral vascular disease, and some clinicians use sweat testing as part of their pre-procedure workup. If your practice sees patients in that pathway, your billing team needs to know that Medicare will not cover the sweat test in that context—full stop.
The real risk is a mixed caseload. Pulmonology and pediatric practices billing sweat tests almost always have a cystic fibrosis indication—they're lower risk here. Vascular surgery practices are where this exclusion bites. If you're in a multi-specialty group that sees both populations, audit your sweat test claims by ordering department before the March 7, 2026 effective date.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Cystic fibrosis diagnosis | Covered | Not specified in NCD 205 | Must document cystic fibrosis as the clinical purpose; check local LCD from your MAC |
| Predictor of sympathectomy efficacy in peripheral vascular disease | Not Covered | Not specified in NCD 205 | Explicitly excluded — CMS considers this use unproven |
CMS Sweat Test Billing Guidelines and Action Items 2026
Sweat test billing under NCD 205 is straightforward in concept but easy to get wrong in execution. Here's what your billing team should do before and after March 7, 2026.
| # | Action Item |
|---|---|
| 1 | Audit sweat test claims by diagnosis before March 7, 2026. Pull all sweat test claims from the past 12 months. Flag any that aren't tied to a cystic fibrosis diagnosis. If you find peripheral vascular disease as the primary or secondary diagnosis driving these tests, that's a compliance issue—not just a billing one. Talk to your compliance officer. |
| 2 | Confirm your ICD-10 coding points to cystic fibrosis. NCD 205 doesn't list specific covered procedure codes, so your diagnosis coding does the heavy lifting. The ICD-10 codes for cystic fibrosis (E84.x range) should appear on every covered sweat test claim. If they don't, the claim has no leg to stand on under this coverage policy. |
| 3 | Check with your Medicare Administrative Contractor for local coverage determinations. CMS sets the national floor here, but your MAC may have a local coverage determination that adds requirements—specific procedure codes, documentation standards, or frequency limits. Don't assume the NCD tells the whole story. |
| 4 | Update your charge capture documentation templates. The ordering provider needs to document why the sweat test is being ordered and confirm it's for cystic fibrosis evaluation. A generic "sweat test ordered" note won't survive a medical necessity review. Build the clinical rationale into your intake or order templates. |
| 5 | Flag peripheral vascular surgery cases for billing review. If your practice performs sympathectomy or treats peripheral vascular disease, add a billing review step for any sweat test order that comes from that care pathway. The exclusion in NCD 205 applies regardless of how the physician frames the order. The question isn't what the doctor intended—it's what Medicare covers. |
| 6 | Train your coding team on the non-covered indication. This isn't common knowledge. Many coders know that sweat tests relate to cystic fibrosis but don't know about the explicit peripheral vascular disease exclusion. One training session now prevents repeated claim denials later. |
If you're uncertain how this policy applies to a specific patient population your practice sees, loop in your compliance officer before the March 7, 2026 effective date. The exclusion language is clear, but applying it to a complex multi-diagnosis case can get tricky fast.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Sweat Test Under NCD 205
This is where the policy creates a real challenge for billing teams.
Covered CPT and HCPCS Codes
NCD 205 does not list specific CPT or HCPCS codes. CMS has not enumerated procedure codes within this national coverage determination.
This means your MAC's local coverage determination—if one exists for your jurisdiction—is the document that will specify which procedure codes apply. Contact your Medicare Administrative Contractor directly to confirm which codes they accept for sweat testing in the cystic fibrosis context. Do not assume a code is covered just because it describes the procedure accurately.
Not Covered Indications
| Indication | Type | Description | Reason |
|---|---|---|---|
| Sweat test for peripheral vascular disease (sympathectomy predictor) | Diagnostic Test | Sweat test used to predict efficacy of sympathectomy | Explicitly excluded under NCD 205 — CMS considers this use unproven and non-covered |
Key ICD-10-CM Diagnosis Codes
NCD 205 does not list specific ICD-10-CM codes. For covered claims, use the appropriate code from the E84 (Cystic fibrosis) category. Your MAC may specify required diagnosis codes in a local coverage determination—verify before billing.
The absence of specific codes in this NCD is worth flagging to your billing director. It's not unusual for older NCDs to predate the granularity of modern code sets. But it does mean your practice carries more documentation burden to prove medical necessity on every claim.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.